科济药业-B：截至2025年6月30日止六个月的中期业绩公告及关于截至2024年12月31日止年度报告的补充公告

CARsgen Therapeutics Holdings Limited 202563020241231 20256302024 1. 202563051賽愷澤®BCMA CAR-TCAR-T 2. 202563029 3. 2025630752024630352277(i)202463054112202563058(ii)20246302461162025630130(iii)20246308647202563039(iv)20256302920246301.6 2025630(1)722024630342270(i)(ii)(iii)(iv)(v) 4. 20256301,261202412311,47921820251,1002028 (1) 賽愷澤®CT053 B(BCMA)CAR-T(NMPA)(R/R MM)3000963.SZ賽愷澤®賽愷澤®2025賽愷澤®20111賽愷澤® CT041 Claudin18.2 (CLDN18.2)CAR-T20256NMPA(CDE)(NDA)Claudin18.2(G/GEJA)20255CDE20253(BTD)II(NCT04581473)The Lancet2025(ASCO) CAR-T THANK-uCAR®CAR-TTHANK-u Plus™THANK-uCAR®NKG2ACAR-TTHANK-u Plus™R/R MM(R/R PCL)BCMACAR-TCT059620255 CAR-TBCMAR/R MMR/R PCLCT0596(THANK-u PlusTM)CD19/CD20BKJ-C2219(THANK-u Plus™)CD38(AML)KJ-C2320THANK-uCAR®KJ-C2114(THANK-uPlus™)NKG2DLKJ-C2526 (THANK-u Plus™) I. CAR-TCAR-TCAR-T II. CAR-TCAR-T 2025N M P AN D AClaudin18.2G/GEJANDACAR-T賽愷澤®THANK-uCAR®CAR-TTHANK-u Plus™CAR-TCAR-T 1. 2.II 3.HKInno.N Corporation195940 賽愷澤®CT053BCMA CAR-T R/R MMBCMA CAR-TBCMA(scFv)CARCAR-TT 賽愷澤®2024223NMPAR/R MM320231賽愷澤®200751,025賽愷澤®賽愷澤®2025賽愷澤®20111賽愷澤® 賽愷澤® LUMMICAR-1202461529(EHA)BCMACAR-T2Phase 2study of fully human BCMA-targeting CAR-T cells (zevorcabtagene autoleucel)in patients with relapsed/refractory multiple myeloma102賽愷澤®ORR92.2% (94/102)VGPR91.2%(93/102)(sCR/CR)71.6% (73/102) LUMMICAR-2 18A.08(3) Claudin18.2 CAR-T Claudin18.2CAR-TClaudin18.2G/GEJAPCClaudin18.2G/GEJAPCCAR-TClaudin18.2CAR-TCAR-T 2025625NMPACDENDAClaudin18.2G/GEJANDAII(CT041-ST-01,NCT04581473)202553CDE II(CT041-ST-01,NCT04581473)TheLancet2025ASCOThe LancetClaudin18.2 CAR-T(CT041-ST-01)IIClaudin-18 isoform 2-specific CAR T-celltherapy (satri-cel) versus treatment of physician’s choice for previously treatedadvanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): arandomised, open-label, phase 2 trial2025ASCOClaudin18.2 CAR-TII(CT041-ST-01)Claudin18.2-specific CAR T cells(Satri-cel) versus treatment of physician’s choice (TPC) for previously treatedadvanced gastric or gastroesophageal junction cancer (G/GEJC): Primary resultsfrom a randomized, open-label, phase II trial (CT041-ST-01)1088820(TPC)(mOS)9.1728TPCmOS3.98(HR 0.288;95% CI: 0.169-0.492)Claudin18.2G/GEJA(PFS)OSCAR-T(RCT)CAR-TRCTCAR-TCAR-TCAR-TCAR-T PCI(CT041-ST-05,NCT05911217)G/GEJA(CT041-CG4010, NCT06857786) C T041- C G4006202463Nature MedicineClaudin18.2 CAR-TIClaudin18.2-specific CAR T cells ingastrointestinal cancers: Phase 1 trial final results202462024ASCO(mPFS)mOS15.295% CI6.816.495%CI7.012OS60.0%95% CI12.6, 88.2 20245CT041Safety and Efficacy of CT041 in PatientsWith Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of TwoEarly-Phase TrialsJournal of Clinical OncologyI/Ib(CT041-CG4006CT041-ST-01) 20242Claudin18.2-CARTMetastatic gastric cancer target lesion complete response withClaudin18.2-CAR T cellsJournal for ImmunoTherapy of Cancer28 2 0 2 39NCT04581473NCT03874897JournalofHematology&OncologyCT041 CAR-TClaudin18.2CT041 CAR T cell therapy forClaudin18.2-positive metastatic pancreatic cancer 18A.08(3) CT011GPC3 CAR-T CT011CAR-T(HCC)GPC3CAR-THCC 20237CAR-GPC3 TCombined local therapy and CAR-GPC3T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concepttreatment strategyCancer CommunicationGPC3 CAR-THCC7 20241CT011NMPAINDGPC3IIIa 18A.08(3)CT011 CT071 – GPRC5D CAR-T CT071CARcelerate®GPRC5DCAR-TR/R MMR/R pPCL(scFv) CARcelerate®CT07130CAR-T CT071(NDMM)(NCT06407947)30EHAGPRC5DCAR-TCT071IA phase I study of GPRC5D targeting CAR T-cell therapy CT071 forhigh-risk newly diagnosed multiple myeloma(ORR)100%70% (7/10)(sCR) CT071R/RMMRR/PCLIIT(NCT05838131)20241266ASHGPRC5DC A R - TC T 0 7 1GPRC5D-Targeted CART-Cell Therapy CT071 for the Treatment ofRefractory/Relapsed Multiple Myeloma 18A.08(3)CT071 CAR-T THANK-uCAR®CAR-TTHANK-uPlus™THANK-uCAR®CAR-TNKG2A CT0590THANK-uCAR®BCMACAR-TCT0590R/R MMCT0590 IIT20241266ASHCT0590BCMANKG2ACAR-TA First-in-Human Study of CT0590,a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA andNKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma CT0596THANK-u Plus™BCMACAR-TCT0596R/R MMR/R PCL2025568R/R MMFC22.5-30 mg/m2350-500 mg/m243(60%)sCR/CR4(80%)(MRD)sCR/CR4(DLT)3(CRS)(ICANS)(GvHD)CT0596R/R MMCAR-T KJ-C2219THANK-u Plus™CD19/CD20CAR-T2024B(R/R B-NHL)2025(SLE)(SSc)KJ-C2219R/R B-NHLSLESSc KJ-C2320THANK-uCAR®CD38CAR-T2024KJ-C2320 KJ-C2114THANK-uPlus™CAR-T KJ-C2526THANK-uPlus™NKG2DLCAR-T 202522580,000,0008%100%92% CAR-TBCMA CAR-TBCD19/CD20CAR-TCAR-T CAR-T CAR-TCAR-T CAR-T (1)CAR-T CAR-TTHANK-uCAR®THANK-uCAR®TCAR-TT(GvHD)(HvGR)TRACβ2(B2M)TCRI(HLA-I)(NK)HLA-ITCAR-TCAR-TNKNKG2ACARTRAC-B2M- TNKG2ANKCAR-TTHANK-uCAR-TNKNKG2A CARTRAC-B2M TNKNKNKG2ANKG2ATHANK-u PlusTMTHANK-u Plus™THANK-uCAR®CAR-TNKG2ANKTHANK-u Plus™THANK-uCAR®THANK-u Plus™NKTHANK-uCAR®BCMACD19/CD20CAR-TNKTHANK-u Plus™CAR-TTHANK-u Plus™CAR-TCAR-T (2) CAR-T30CARcelerate®CAR-TCARcelerate®CAR-TCARcelerate®CT071MMpPCL (3) •CycloCAR®CAR-TIL-7CCL21IL-7CAR-TCAR-TCCL21TCAR-TCycloCAR